US3381029A - A-norprogesterone derivatives - Google Patents

A-norprogesterone derivatives Download PDF

Info

Publication number
US3381029A
US3381029A US399838A US39983864A US3381029A US 3381029 A US3381029 A US 3381029A US 399838 A US399838 A US 399838A US 39983864 A US39983864 A US 39983864A US 3381029 A US3381029 A US 3381029A
Authority
US
United States
Prior art keywords
dione
acetate
norpregnene
norpregnadiene
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US399838A
Inventor
Seymour D Levine
Patrick A Diassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR43865A priority Critical patent/FR5216M/fr
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Priority to US399838A priority patent/US3381029A/en
Priority to GB40200/65A priority patent/GB1126686A/en
Priority to US708734A priority patent/US3449377A/en
Priority to US708736A priority patent/US3424786A/en
Priority to US708737A priority patent/US3424787A/en
Priority to US708735A priority patent/US3439023A/en
Application granted granted Critical
Publication of US3381029A publication Critical patent/US3381029A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Definitions

  • This invention relates to and has as its object the provision of new physiologically active steroids, methods for their production and novel intermediates useful in said preparation.
  • this invention relates to the provision of steroids of the formulae wherein X is halogen (e.g., chloro, bromo, fluoro) and R is selected from the group consisting of hydrogen and acyl.
  • X is halogen (e.g., chloro, bromo, fluoro) and R is selected from the group consisting of hydrogen and acyl.
  • the preferred acyl radicals are those of hydrocarbon carboxylic acids of less than twelve carbon atoms, as exemplified by the lower alkanoic acids (e.g., acetic, propionic butyric and tert-pentanoic acid), the lower alkenoic acids, the monocyclic aryl carboxylic acids (e.g., benzoic and toluic acids), the monocyclic aryl lower alkanoic acids (e.g., phenacetic and li-phenylpropionic acid), the cycloalkane carboxylic acids and the cycloalkene carboxylic acids.
  • the lower alkanoic acids e.g., acetic, propionic butyric and tert-pentanoic acid
  • the monocyclic aryl carboxylic acids e.g., benzoic and toluic acids
  • the monocyclic aryl lower alkanoic acids e.g., phenacetic and li-
  • the compounds of this invention possess progestational activity and thus may be employed instead of progesterone, for example, in the treatment of habitual abortion for which purpose they can be administered in the same manner as progesterone, for example, the dosage being adjusted for the relative potency of the particular steroidt
  • the final products of the instant invention may be prepared by the processes of this invention which entails a number of steps beginning with A-norprogesterone as starting material.
  • A-norpr0gester one is enol acylated as by treatment with an acid anhydride, for example, acetic anhydride in the presence of a peracid, for example, perchloric acid, to yield the 17 (20)- dehydro-ZO-acyloxy derivative (Compounds A), which are new compounds of the instant invention.
  • Compounds A are then treated with a peracid, for example, m-chloropherbonzoic acid, to yield the 17-substituted A-norprogesterone (Compounds B), which are also new compounds of this invention.
  • a peracid for example, m-chloropherbonzoic acid
  • Compounds B are then dehydrogenated as by treatment with a dehydrogenating agent, for example, 2,3-dichlro- 5,6-dicyanobenzoquinone to yield the A -A-norpregnadiene derivatives (Compounds C), which are new compounds of this invention.
  • a dehydrogenating agent for example, 2,3-dichlro- 5,6-dicyanobenzoquinone
  • Compounds C are then treated with a peracid, such as m-chloroperbenzoic acid to yield the 6,7-oxido derivatives (Compounds D) which are also new compounds of the instant invention.
  • a peracid such as m-chloroperbenzoic acid
  • Compounds D Treatment of Compounds D with 1 mole equivalent of a hydrohalic acid, for example, hydrochloric acid or hydrobromic acid yields the 6-halo-7-hydroxy-A -A-norpregnene derivatives (Compounds F), which are also new compounds of the instant invention.
  • a hydrohalic acid for example, hydrochloric acid or hydrobromic acid
  • Compounds D may be treated with an excess of a hydrohalic acid, e.g., hydrobromic or hydrochloric acid at an elevated temperature, to yield the 6- chl0ro-A -A-norpregnadiene derivatives (Compounds E), which are also new compounds of the instant invention.
  • a hydrohalic acid e.g., hydrobromic or hydrochloric acid at an elevated temperature
  • EXAMPLE 1 A -A-norpregnadiene-2-one-20-ol acetate (I) An ice-cold solution of 1.5 ml. of acetic anhydride containing three drops of perchloric acid is added to a solution of 250 mg.'of A-norprogesterone in 8 ml. of carbon tetrachloride and 20 ml. of benzene and left at room temperature for one day. The reaction mixture is poured into ice-water and additional carbon tetrachloride is added. The organic layer is separated and washed with a saturated sodium bicarbonate solution and 8% salt solution, dried over sodium sulfate, and evaporated to dryness to give a 280 mg. residue.
  • EXAMPLE 2 A -A-norpregnene-2,20-dione-l7a-o1 (III) A mixture of 150 mg. of m-chloroperbenzoic acid and 225 mg. of A -A-norpregnadiene-2-one-20-ol acetate in 4 ml. of chloroform is stirred at room temperature for two hours. The chloroform solution is washed five times with 5% sodium hydroxide solution, twice with 8% salt solution, dried over sodium sulfate and evaporated to dryness to give a gum. The gum is treated with a hot solution of 280 mg. of potassium hydroxide in 5 ml. of methanol and stirred at room temperature for thirty-five minutes and diluted with water. The precipitate is collected by filtration and washed with water and dried to give 100 mg. of A -A-norpregnene-2,20-dione-17a-ol having a melting point of 210-212. The analytical sample is max.
  • the filtrate is diluted with additional chloroform to a total volume of ml. and passed through 'a 40 g. neutral alumina (Activity I) column.
  • the column is eluted with 420 ml. of chloroform, and the eluate is evaporated to give a 1.42 g. residue, which is refluxed in 30 ml. of coll1d1ne for seventy-rive minutes, cooled to room temperature and diluted with chloroform.
  • the organic layer is washed with 2 N hydrochloric solution, saturated sodium bicarbonate solution and 8% salt solution, dried over sodiurn sulfate and evaporated to dryness.
  • a -A-norpregnadiene-2,20- dione-17a-o1 acetate in 30 ml. of methanol is treated with 3 ml. of potassium carbonate solution and stirred at room temperature for eighteen hours.
  • the reaction mixture is diluted with water and the precipitate collected by filtration to give 303 mg. of A -A-norpregnadiene-2,20-
  • the analytical sample is prepared by recrystallization from acetonitrile, M.P. 247-248", [ml- +42 (EtOH);
  • EXAMPLE 7 6a,7a-oxido-A -A-norpregnene-2,20-dione-17a-ol acetate (VH)
  • a mixture of 320 mg. of A fi-A-norpregnadiene-Z,20- dione-17a-ol acetate 'and 600 mg. of m-chloroperbenzoic acid in 40 ml. of methylene chloride is left at room temperature for sixty-six hours.
  • the organic layer is washed with a saturated sodium bicarbonate solution, 5% sodium sulfite solution, and 8% salt solution, dried over sodium sulfate 'and evaporated to dryness. Crystallization of the residue from ether-chloroform gives 191 mg.
  • a compound selected from the group consisting of steroids of the formulae and 8 2. 6,8-chl0ro-A -A-norpregnene-2,2O-dione-7u,17a-diol 17-acetate -(X). 3. 6-chloro-A -A-norpregnadiene-2,20-dione-l7a-01 acetate (VIII). 4. 6-ch1ore-A -A-norpregnadiene-2,20-dione-1711-01. 5. 6 3-chloro-A -A-norpregnene-2,20-dione-7a,17a-dioldiacetate. 6. 6-bromo-A -A-norpregnadiene-2,2O-dione-17a-ol acetate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Description

United States Patent 3,381,029 A-NORPROGESTERONE DERIVATIVES Seymour D. Levine, Princeton, and Patrick A. Diassi,
Westfield, N.J., assignors, by mesne assignments, to E. R. Squibb & Sons, Inc., New York, N.Y., a corporation of Delaware No Drawing. Filed Sept. 28, 1964, Ser. No. 399,838 6 Claims. (Cl. 260-488) This invention relates to and has as its object the provision of new physiologically active steroids, methods for their production and novel intermediates useful in said preparation.
More particularly, this invention relates to the provision of steroids of the formulae wherein X is halogen (e.g., chloro, bromo, fluoro) and R is selected from the group consisting of hydrogen and acyl.
The preferred acyl radicals are those of hydrocarbon carboxylic acids of less than twelve carbon atoms, as exemplified by the lower alkanoic acids (e.g., acetic, propionic butyric and tert-pentanoic acid), the lower alkenoic acids, the monocyclic aryl carboxylic acids (e.g., benzoic and toluic acids), the monocyclic aryl lower alkanoic acids (e.g., phenacetic and li-phenylpropionic acid), the cycloalkane carboxylic acids and the cycloalkene carboxylic acids.
The compounds of this invention possess progestational activity and thus may be employed instead of progesterone, for example, in the treatment of habitual abortion for which purpose they can be administered in the same manner as progesterone, for example, the dosage being adjusted for the relative potency of the particular steroidt The final products of the instant invention may be prepared by the processes of this invention which entails a number of steps beginning with A-norprogesterone as starting material. The process of the instant invention may CH 1 s C=O -OR In the first step of the instant process, A-norpr0gester one is enol acylated as by treatment with an acid anhydride, for example, acetic anhydride in the presence of a peracid, for example, perchloric acid, to yield the 17 (20)- dehydro-ZO-acyloxy derivative (Compounds A), which are new compounds of the instant invention.
Compounds A are then treated with a peracid, for example, m-chloropherbonzoic acid, to yield the 17-substituted A-norprogesterone (Compounds B), which are also new compounds of this invention.
Compounds B are then dehydrogenated as by treatment with a dehydrogenating agent, for example, 2,3-dichlro- 5,6-dicyanobenzoquinone to yield the A -A-norpregnadiene derivatives (Compounds C), which are new compounds of this invention.
Compounds C are then treated with a peracid, such as m-chloroperbenzoic acid to yield the 6,7-oxido derivatives (Compounds D) which are also new compounds of the instant invention.
Treatment of Compounds D with 1 mole equivalent of a hydrohalic acid, for example, hydrochloric acid or hydrobromic acid yields the 6-halo-7-hydroxy-A -A-norpregnene derivatives (Compounds F), which are also new compounds of the instant invention.
Alternatively, Compounds D may be treated with an excess of a hydrohalic acid, e.g., hydrobromic or hydrochloric acid at an elevated temperature, to yield the 6- chl0ro-A -A-norpregnadiene derivatives (Compounds E), which are also new compounds of the instant invention.
The invention may be illustrated by the following examples:
EXAMPLE 1 A -A-norpregnadiene-2-one-20-ol acetate (I) An ice-cold solution of 1.5 ml. of acetic anhydride containing three drops of perchloric acid is added to a solution of 250 mg.'of A-norprogesterone in 8 ml. of carbon tetrachloride and 20 ml. of benzene and left at room temperature for one day. The reaction mixture is poured into ice-water and additional carbon tetrachloride is added. The organic layer is separated and washed with a saturated sodium bicarbonate solution and 8% salt solution, dried over sodium sulfate, and evaporated to dryness to give a 280 mg. residue. Plate chromatography of the residue using silica gel as the adsorbent and chloroform containing 1% of methanol as the developing solvent gives a major band at about Rf 0.4, which is detectable by ultraviolet. Elution with ethyl acetate and evaporation to dryness gives a 232 mg. residue. Crystallization of the residue from etherhexane gives 21 mg. of A -A-norpregnadiene-2-one- 20-01 acetate having a melting point of 131-132. Recrystallization from isopropyl ether gives the analytical sample having melting point 131-132; (EtOH);
1 Si(CH 9.11 (s, 18-Me); 8.83 (s, 19-Me); 8.21 (s, 21-Me); 7.90 (s, ZO-acetate) and 4.27 (s, 3-H).
Analysis.Calcd for C H O (342.46): C, 77.15; H, 8.83. Found: C, 77.20; H, 8.79.
EXAMPLE 2 A -A-norpregnene-2,20-dione-l7a-o1 (III) A mixture of 150 mg. of m-chloroperbenzoic acid and 225 mg. of A -A-norpregnadiene-2-one-20-ol acetate in 4 ml. of chloroform is stirred at room temperature for two hours. The chloroform solution is washed five times with 5% sodium hydroxide solution, twice with 8% salt solution, dried over sodium sulfate and evaporated to dryness to give a gum. The gum is treated with a hot solution of 280 mg. of potassium hydroxide in 5 ml. of methanol and stirred at room temperature for thirty-five minutes and diluted with water. The precipitate is collected by filtration and washed with water and dried to give 100 mg. of A -A-norpregnene-2,20-dione-17a-ol having a melting point of 210-212. The analytical sample is max.
max.
4 prepared by recrystallization from chloroform-ether, M.P.
2.90, 5.87, 5.95, 6.17 A553 234 mp. (15,800); 300 mp. (143) 'r Sl(CH 9.24 (s, 18-Me), 8.82 (s, l9-Me), 7.72 (s, 2l-Me); 7.15 (s, 17-hydroxy) and 4.25 (s, 3-H).
Analysis.--Calcd for C H O (316.42): C, 75.91; H, 8.92. Found: C, 76.09; H, 8.74.
EXAMPLE 3 A -A-norpregnene-2,20-dione-17u-ol acetate (H) A mixture of 61 mg. of A -A-nol'pregnene-2,20-di0ne- 1711-01 and 61 mg. of p-toluenesulfonic acid monohydrate in 0.6 ml. of acetic anhydride and 3 ml. of glacial acetic acid is left at room temperature for twenty-two hours, diluted with water and neutralized with potassium carbonate. The reaction mixture is extracted three times with ether, and the combined ether extracts are washed with 8% salt solution, dried over sodium sulfate and evaporated to dryness. Crystallization of the residue from isopropyl ether gives 50 mg. of A -A-norpregnene-2,20-dione- 17a-ol acetate having a melting point of 182-184. The analytical sample is prepared by recrystallization from isopropyl ether, M.P. 1865-1875", [a] 47 (EtOH);
a 5.78, 5.85, 5.94 (3b.), 6.17 234 mp (16,300);
max.
'r Si(CH 9.31 (s, 18-Me), 8.81 (s, 19-Me), 7.95 (S, 17-acetate), 7.90 (s, 21-Me) and 4.26 (s, 3-H).
Analysis.Calcd for C H O (358.46): C, 73.71; H, 8.44. Found: C, 73.75; H, 8.34.
EtOH max.
EXAMPLE 4 A -A-norpregnene-2,20-dione-17a-ol acetate (II) EXAMPLE 5 A -A-Norpregnadiene-Z,20-dione-17a-ol acetate (IV) Hydrogen chloride is bubbled into a solution of 1.40 g. of A -A-norpregnene-2,20-dione-17a-ol acetate and 1.0 g. of 2,3-dichloro-5,=6-dicyanobenzoquinone in 30 ml. of droxane for five minutes and the flask is left at room temperature overnight. The hydroquinone is filtered and the filtrate is evaporated to dryness. The residue is treated with chloroform and additional hydroquinone is filtered.
The filtrate is diluted with additional chloroform to a total volume of ml. and passed through 'a 40 g. neutral alumina (Activity I) column. The column is eluted with 420 ml. of chloroform, and the eluate is evaporated to give a 1.42 g. residue, which is refluxed in 30 ml. of coll1d1ne for seventy-rive minutes, cooled to room temperature and diluted with chloroform. The organic layer is washed with 2 N hydrochloric solution, saturated sodium bicarbonate solution and 8% salt solution, dried over sodiurn sulfate and evaporated to dryness. Plate chromatography of the residue using neutral alumina (Activity V) as the adsorbent and chloroform containing 10% hexane as the developing solvent gives a major band at about R 0.5, which is detectable by ultraviolet. Elution with ethyl acetate gives a residue which is crystallized from isopropyl ether to give 764 mg. of A -A-norpregnadiene-2,20- dione-17oc-01 acetate having a melting point of l75-l76. The analytical sample is prepared by recrystallization EXAMPLE 6 A -A-NOr regnadiene-Z,ZO-dione-178-01 (V) A mixture of 500 mg. of A -A-norpregnadiene-2,20- dione-17a-o1 acetate in 30 ml. of methanol is treated with 3 ml. of potassium carbonate solution and stirred at room temperature for eighteen hours. The reaction mixture is diluted with water and the precipitate collected by filtration to give 303 mg. of A -A-norpregnadiene-2,20-
dione-l7a-ol having a melting point of 241-243. The analytical sample is prepared by recrystallization from acetonitrile, M.P. 247-248", [ml- +42 (EtOH);
A511 2.91, 5.87, 5.99, 6.20 and 6.35 1; kite? 278 m (22,600); r Si(CH3)4 9.18 (s, 18-Me), 8.89 (s, 19-Me), 7.71 (s, 21-Me), 7.12 (s, 17-hydroxy), 4.26 (s, 3-H); 3.83 (d, d, 1 cps., 9.5 cps. 6-H), 3.48 (d, d, 2 cps. 7-H) AHHIYSZ Sr-CZ-ICd for CH2303 C, H, 8.34. Found: C, 76,23; H, 8.44.
EXAMPLE 7 6a,7a-oxido-A -A-norpregnene-2,20-dione-17a-ol acetate (VH) A mixture of 320 mg. of A fi-A-norpregnadiene-Z,20- dione-17a-ol acetate 'and 600 mg. of m-chloroperbenzoic acid in 40 ml. of methylene chloride is left at room temperature for sixty-six hours. The organic layer is washed with a saturated sodium bicarbonate solution, 5% sodium sulfite solution, and 8% salt solution, dried over sodium sulfate 'and evaporated to dryness. Crystallization of the residue from ether-chloroform gives 191 mg. of 611,711 oxido-M-A-norpregnene-Z,20-dione-1701-01 acetate having a melting point of 202-204". The analytical sample is prepared by recrystallization from acetone-hexane, M.P. 232-233 [01], 15 (EtOH);
, x55; 5.78, 5.86, and 6.13 1 A533, 235 mp 11,700)
1- Si(CH 9.28 (s, 18-Me), 8.88 (s, 19-Me), 7.94 (s, 17-acetate), 7.88 (s, 2l-Me), 6.61 (d,d 1 cps., 3.5 cps.; 7-H), 6.18 (d, 3.5 cps., 6-H), 3.78 (s, 3-H).
Analysis.-Calcd for C H O (372.44): C, 70.94; H, 7.58. Found: C, 70.97; H, 7.57.
EXAMPLE 8 6:2,7a-oxido-A -A-norpregnene-2,2O-dione-17a-ol (VI) Following the procedure of Example 6, but employing 611,70: oxido A -A-norpregnene-2,20-dione-17a-ol acetate, there is obtained 6a,7a oxido-A -A-norpregnene- 2,20-dione-17a-ol.
EXAMPLE 9 6 ,B-chloro-A -A-norpregnene-2,20-dione-7a, 17a-diol 17-acetate (X) A solution of 61.5 mg. of 6a,7a-oxido-A -A-norpregnene-2,20-dione-17a-ol acetate in 6 ml. of chloroform is treated with a slight excess of hydrogen chloride in chloroform and left at room temperature for two and onehalf hours. The reaction mixture is diluted with water and the layers separated. The aqueous phase is extracted with additional chloroform. The chloroform extracts are washed with an 8% salt solution, dried over sodium sulfate and evaporated to dryness. Crystallization of the residue from ethyl acetate-isopropyl ether gives 50 mg. of 6B chloro-A -A-norpregnene-2,20-dione-7a,17a-diol l7-acetate having a melting point of 236-238. The analytical sample is prepared by recrystallization from ethyl acetate-isopropyl ether, M.P. 246.5247.5, [(111 -76 (EtOH);
2.86, 5.85, and 6.16,; x5 3 235 (14,800)
T Si(CH 9.25 (s, 18-Me), 8.58 (s, 19-Me), 1.94 (s, 17- acetate), 7.90 (s, 21-Me), 5.93 (m, 7-H), 5.20 (d, 2.5 cps., 6-H), 3.92 (s, 3-H).
Analysis.-Calcd for C H O Cl (408.91): C, 64.60; H, 7.15: Found: C, 64.57; H, 7.16.
EXAMPLE l0 6-chloro-A -A-norpregnadiene-2,20-dione-17a-ol acetate (VIII) Hydrogen chloride is passed into a solution of 335 mg. of 6a,7a-oxido-A -N-norpregnene-2,20-dione-178-01 acetate in 30 ml. of chloroform for three minutes. The reaction mixture is left at room temperature for two hours, and then at for one day. The reaction mixture is washed with water, saturated sodium bicarbonate solution and 8% salt solution, dried over sodium sulfate and evaporated by dryness. Plate chromatography of the residue using neutral alumina (Activity V) as the adsorbent and chloroform containing 20% hexane as the developing solvent gives a major band at about R 0.8, which is detectable by ultraviolet. Elution with ethyl acetate gives a residue which is crystallized from isopropyl etherethyl acetate to give 177 mg. of 65-chloro-A A-norpregnadiene-2,20-dione-1178-01 acetate having a melting point of 183-184. The analytical sample is prepared by Analysis.Calcd for C22H2704C1 (390.89): C, 67.66; H, 6.96; CI, 9.07. Found: C, 67.42; H, 7.00; Cl, 9.09.
EtOH Mm.
EXAMPLE 11 6-chloro-A -A-norpregnadiene-2,20-dione-17a-ol Following the procedure of Example 6, but employing 6-chloro-A -A-norpregnadiene-2,20-dione-17a-ol acetate,
. there is obtained 6-chloro-A -A-norpregnadiene-2,20-
dione- 1704-01.
EXAMPLE 12 6,8-chloro-A -A-norpregnene-2,20-dione-7a, 17a-diol-diacetate Following the procedure of Example 9, but substituting 6a,7a-oxido-A -A-norpregnene-2,20-dione-17a-ol, there is obtained 6/3-chloro-A -A-norpregnene-2,20-dione-7a- 17a-di0l.
EXAMPLE 13 6-bromo-A -A-norpregnadiene-Z,20-dione-17a-ol acetate Following the procedure of Example 10, but substituting hydrogen bromide for hydrogen chloride, there is obtained 6-bromo-A -A-norpregnadiene-2,20-dione-17aol acetate.
The invention may be variously otherwise embodied within the scope of the appended claims.
What is claimed is:
7 1. A compound selected from the group consisting of steroids of the formulae and 8 2. 6,8-chl0ro-A -A-norpregnene-2,2O-dione-7u,17a-diol 17-acetate -(X). 3. 6-chloro-A -A-norpregnadiene-2,20-dione-l7a-01 acetate (VIII). 4. 6-ch1ore-A -A-norpregnadiene-2,20-dione-1711-01. 5. 6 3-chloro-A -A-norpregnene-2,20-dione-7a,17a-dioldiacetate. 6. 6-bromo-A -A-norpregnadiene-2,2O-dione-17a-ol acetate.
References Cited Chemical Abstracts, 1963: 58: 11449. Chemical Abstracts, 1961: 55: 22376. Chemical Abstracts, 1961: 55: 22377.
LORRAINE A. WEINBERGER, Primary Examiner.
V. GARNER, Assistant Examiner. 1

Claims (1)

1. A COMPUND SELECTED FROM THE GROUP CONSISTING OF STEROIDS OF THE FORMULAE
US399838A 1964-09-28 1964-09-28 A-norprogesterone derivatives Expired - Lifetime US3381029A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR43865A FR5216M (en) 1964-09-28 1963-07-25
US399838A US3381029A (en) 1964-09-28 1964-09-28 A-norprogesterone derivatives
GB40200/65A GB1126686A (en) 1964-09-28 1965-09-21 A-nor-steroids
US708734A US3449377A (en) 1964-09-28 1967-11-13 Synthesis of steroids
US708736A US3424786A (en) 1964-09-28 1967-11-13 Derivatives of a norprogesterone
US708737A US3424787A (en) 1964-09-28 1967-11-13 Derivatives of a-norprogesterone
US708735A US3439023A (en) 1964-09-28 1967-11-13 Derivatives of a-norprogesterone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US399838A US3381029A (en) 1964-09-28 1964-09-28 A-norprogesterone derivatives

Publications (1)

Publication Number Publication Date
US3381029A true US3381029A (en) 1968-04-30

Family

ID=23581165

Family Applications (1)

Application Number Title Priority Date Filing Date
US399838A Expired - Lifetime US3381029A (en) 1964-09-28 1964-09-28 A-norprogesterone derivatives

Country Status (3)

Country Link
US (1) US3381029A (en)
FR (1) FR5216M (en)
GB (1) GB1126686A (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
FR5216M (en) 1967-07-03
GB1126686A (en) 1968-09-11

Similar Documents

Publication Publication Date Title
US2666769A (en) 17-glycolyl-estradiols
US3381029A (en) A-norprogesterone derivatives
US3407212A (en) Processes for cyclizing compounds having the 8a carbamyl,2- oxo-naphthalene moiety to pyrrolidones and reacting the latter with a sulfonyl halide
US3502700A (en) 17-esters of 9alpha,21-dihalo-11beta,17alpha-dihydroxyprogesterones
US3439023A (en) Derivatives of a-norprogesterone
US2880233A (en) Compounds of the perhydrochrysene and related series and preparation thereof
US3424787A (en) Derivatives of a-norprogesterone
US3449377A (en) Synthesis of steroids
US3424786A (en) Derivatives of a norprogesterone
US3515719A (en) 7-methyl-6,19-epoxy steroids of the androstane series
US3296300A (en) 5 beta-alkanoyl-alpha-norandrostanes
Sondheimer et al. Steroidal Sapogenins. XXXIII. 1 Aromatization Experiments in the Diosgenin Series
US3103510A (en) Cx c cx o oej
US3365466A (en) 2-oxa-androstanes and their preparation
US3280114A (en) 17-lowerr alkyl ethers of 6-chloro-delta4, 6-pregnadien-17alpha-ol-3, 20-dione
US3463792A (en) Synthesis of steroids
US3461124A (en) Steroids of the 3,4-diaza-delta**1,4-androstadiene series
US3083200A (en) 22-halo-20-spirox-4-ene-3, 21-diones and process for preparation
US3367965A (en) delta3, 6-a-norandrostadienes and intermediates
US3420855A (en) Synthesis of steroids
US2816120A (en) 9alpha-fluoro-4, 11beta-dihydroxyprogesterone and process
US3359280A (en) Ketals of 5-alkanoyl-alpha-norandrostane-2-ones
US3385883A (en) A-nor-d-homosteroids
US3412112A (en) 3beta, 10alpha-17beta-triol-gon-4-enes and derivatives thereof
US3098851A (en) 17alpha-alkynyl-2beta-halo-5alpha-androstane-3alpha, 17beta-diols, esters thereof, and intermediates thereto